Category Archives: IP
The FTC's Beef with Pay For Delay: What's the Fuss?
Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive on the grounds that these settlements amount to a restraint of trade under the commerce clause of the [...]
Also posted in Legal, Market Access, Regulatory Tagged Actavis, Andro-Gel, FTC, Hatch-Waxman, Supreme Court 1 Comment
FTC v. Actavis: The Wrong End of the Telescope
by Traci Medford-Rosow and Peter C. Richardson
On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case. The court’s grant of certiorari marked the latest chapter in a decade-long effort by the FTC to have the court rule on the festering issue of whether pay-for-delay provisions in [...]
Also posted in Legal, Market Access, Op-Ed, Regulatory, Strategy Tagged Hatch-Waxman, pay-for-delay 1 Comment
Emerging Countries' R&D: A Contest, but No Wipe Out
Emerging country markets are widely viewed as Big Pharma’s ace in the hole to replace declining rates of innovation in the US and Europe, with numerous studies claiming the BRICK nations (the ‘K’ is from South Korea) are at the center of a revolutionary global shift in the source points for new ideas — what [...]
Also posted in Emerging Markets, Global, R&D Tagged BRIC, BRICK countries, Emerging Markets, R&D 2 Comments
Global Patent Management Made Easy
Patent Management Made Easy
Even with a successfully launched start-up or spin-out to your name, you may still be tempted to close your eyes to the complexities of IP. But it’s actually very simple, writes Jason Rutt.
So, you have done it. You have left big business or forsaken the dusty halls of academia to launch that [...]
Also posted in Europe, Global, Guest Blog, Legal Tagged IP, Law, Patent, patent management Leave a comment

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling